NYSE · MED
Medifast, Inc.
Consumer Cyclical · Personal Products & Services
$11.61▼ 0.85% ($0.10)at close
As of 4:00 PM ET
Market cap
$129.09M
P/E
-4.98
EPS (TTM)
-$2.30
Next earnings
Nov 9, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 9.3%
USD · TTM ending Jun 30, 2026 · Price used $11.61 · Price Sep 29, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 16.11% over the last year. Revenue declined 34.03% over the trailing twelve months. Operating margin moved from 0.1% to -5.46%. Free cash flow grew 265.69% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -5.46%. Revenue declined 34.03% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
6
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 9, 2026
Q3 FY26 · EPS est -$0.35 · Revenue est $71.3M
View
Institutional Sentiment
Medifast, Inc. · MED
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.